XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Credit: Innoviva. Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial). Xacduro ® (sulbactam for injection; ...

Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...

Joshua D. Hartzell, MD, Assistant Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Infectious Disease Fellow, Department of Internal Medicine, Walter ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved sulbactam-durlobactam for nosocomial pneumonia caused by drug-resistant Acinetobacter baumannii ...

Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial ...

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter baumannii bacteria; these pathogens are a major reason why people on ventilators ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S.